115 related articles for article (PubMed ID: 2912520)
21. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
[TBL] [Abstract][Full Text] [Related]
22. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
23. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
25. VP-16 and adriamycin in patients with advanced breast cancer.
Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M
Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491
[TBL] [Abstract][Full Text] [Related]
26. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
Allegra JC
Semin Oncol; 1983 Jun; 10(2 Suppl 2):23-8. PubMed ID: 6306835
[TBL] [Abstract][Full Text] [Related]
28. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
[TBL] [Abstract][Full Text] [Related]
29. Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer.
Mortimer J; Livingston RB; Hardesty IJ; Groppe CW; Purvis JD; Gupta M; Flournoy N
Cancer Treat Rep; 1984; 68(7-8):1017-8. PubMed ID: 6744334
[TBL] [Abstract][Full Text] [Related]
30. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
[TBL] [Abstract][Full Text] [Related]
32. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
33. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
35. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
37. Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer.
Abeloff MD; Beveridge RA; Donehower RC; Fetting JH; Davidson NE; Gordon GG; Waterfield WC; Damron DJ
J Natl Cancer Inst; 1990 Apr; 82(7):570-4. PubMed ID: 2313733
[TBL] [Abstract][Full Text] [Related]
38. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
39. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
[TBL] [Abstract][Full Text] [Related]
40. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Hofheinz RD; Hartung G; Samel S; Hochhaus A; Pichlmeier U; Post S; Hehlmann R; Queisser W
Onkologie; 2002 Jun; 25(3):255-60. PubMed ID: 12119460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
